

Muthalagu Ramanathan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1543230/publications.pdf>

Version: 2024-02-01

27
papers

840
citations

840776

11
h-index

713466

21
g-index

27
all docs

27
docs citations

27
times ranked

1849
citing authors

#	ARTICLE	IF	CITATIONS
1	Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. <i>Blood</i> , 2016, 127, 2427-2438.	1.4	403
2	Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1796-1803.	2.0	73
3	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1493-1503.	2.0	55
4	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1777-1784.	2.0	50
5	Allotransplantation for Patients Age ≥ 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
6	Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1893-1899.	2.0	34
7	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33
8	Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 478-485.	2.0	31
9	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479.	2.0	21
10	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 269-277.	2.0	19
11	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 971-979.	2.0	16
12	Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 264.e1-264.e7.	1.2	13
13	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 552-558.	2.0	12
14	Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma. <i>Advances in Hematology</i> , 2014, 2014, 1-12.	1.0	11
15	Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 3348-3360.	1.3	11
16	Elderly do benefit from induction chemotherapy: High dose mitoxantrone-based ($\times 5 + 1 \times$) induction chemotherapy regimen in newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, 209-215.	4.1	8
17	Validation of an electronic algorithm for Hodgkin and non-Hodgkin lymphoma in ICD-10-CM. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 910-917.	1.9	5
18	Early relapse of Burkitt lymphoma heralded by a bone marrow necrosis and numb chin syndrome successfully treated with allogeneic stem cell transplantation. <i>Leukemia Research Reports</i> , 2014, 3, 51-53.	0.4	3

#	ARTICLE	IF	CITATIONS
19	Elotuzumab-based maintenance therapy following autologous stem cell transplant in multiple myeloma deepens post-transplant responses. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 85, 102482.	1.4	2
20	Early CMV Reactivation Still Remains a Cause of Increased Transplant Related Mortality in the Current Era: A CIBMTR Analysis. <i>Blood</i> , 2014, 124, 47-47.	1.4	2
21	High Complete Remission (CR) Rates and Reduced Early Mortality with High Dose Ara-c (HiDAC) and Mitoxantrone (MITO) Induction Chemotherapy for Older (age>60) High Risk Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2010, 116, 3290-3290.	1.4	1
22	Impact of pretransplant mutation status on survival after allogeneic stem cell transplant for acute myeloid leukemia. <i>EJHaem</i> , 2021, 2, 514-519.	1.0	0
23	Autologous (Auto) Peripheral Blood Stem Cell (SCT) As a Consolidation Therapy for Patients with Acute Myeloid Leukemia (AML) in 1st Complete Remission (CR): A Single Institution Experience. <i>Blood</i> , 2011, 118, 4505-4505.	1.4	0
24	High Dose Mitoxantrone Based "5+1" Induction Chemotherapy Regimen in Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1430-1430.	1.4	0
25	Hematopoietic Cell Transplant - Comorbidity Index (HCT-CI) Score Is a Useful Tool for Predicting Induction Mortality and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 1396-1396.	1.4	0
26	The Incidence and Impact of Clostridioides Difficile Infection (CDI) on Outcomes after Allogeneic Hematopoietic Cell Transplant (alloHCT) - a CIBMTR Study. <i>Blood</i> , 2021, 138, 2894-2894.	1.4	0
27	Treatment of Acute Graft-versus-Host Disease in Liver Transplant Recipients. <i>Case Reports in Transplantation</i> , 2021, 2021, 1-6.	0.3	0